Hagberg KW, Persson R, Vasilakis-Scaramozza C, et al. - In this cohort study of individuals with treated psoriasis or psoriatic arthritis (PsA), researchers applied MarketScan (2014– 2018) to determine rates of herpes zoster, hepatitis C (HepC) and tuberculosis (TB) with apremilast matched to other systemic treatments. A total of 131,604 individuals were recruited in this study. After March 21, 2014, individuals were exposed from first apremilast [APR], DMARD, TNF-inhibitor [TNF], IL-inhibitor [IL], or corticosteroids [CS] prescription. This study estimated incidence rates (IRs) [95% confidence intervals] per 1000 patient-years. The study found variations in rates of herpes zoster after the treatment: highest among those who received polytherapy, lowest in users of apremilast only. For all exposures, IRs for HepC and TB were low.